• Dursun Fırat Ergül, Serdar Ekemen, and Birgül Büyükkıdan Yelken.
• Department of Anaesthesiology and Reanimation, Unit of Intensive Care, Osmangazi University Faculty of Medicine, Eskişehir, Turkey.
• Turk J Anaesthesiol Reanim. 2015 Oct 1; 43 (5): 347-51.

AbstractIn the language of the streets, 'bonzai', known as '1-naphthalenyl of methanol', also known as JWH-18 group, is a drug belonging to the group of synthetic cannabinoids. At the beginning of 2004, it started to be sold on the internet and it is seen that private markets. It has structurally similar chemical characteristics as delta 9-tetrahydrocannabinol (THC), the active substance in marijuana. In 2013, in a study conducted by the European Monitoring Centre of Drugs and Drug Addiction (EMCDDA), 102 varieties of synthetic cannabinoids were identified; however, more than 200 substances have been reported since 1997. In this study, we report the difficulties in the clinical course, treatment and management of six patients that had a use history of bonzai although it was not detected in blood in a short period of time in the intensive care unit.

5 keywords...

hide…